Menu Search
Equities

Shenzhen Neptunus Interlong Bio-technique Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8329:HKG.HS

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Actions
  • Price (HKD)0.159
  • Today's Change-0.002 / -1.24%
  • Shares traded110.00k
  • 1 Year change-1.24%
  • Beta0.0987
Data delayed at least 15 minutes, as of Feb 12 2026 06:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shenzhen Neptunus Interlong Bio-technique Co Ltd is a China-based company principally engaged in the research and development, manufacturing and selling of medicines and medical devices, and the purchase and sales of medicines, healthcare food products and medical devices. The Company operates its businesses through two segments. The Manufacturing and Selling of Medicines and Medical Devices segment is mainly engaged in manufacturing, sales of medicines and medical devices. The Sales and Distribution of Medicines, Healthcare Products and Medical Devices segment is mainly engaged in sales and distribution of medicines, healthcare products and medical devices. The Company mainly operates its businesses in the domestic market.

  • Revenue in HKD (TTM)1.12bn
  • Net income in HKD6.99m
  • Incorporated1994
  • Employees1.47k
  • Location
    Shenzhen Neptunus Interlong Bio-technique Co Ltd1F, Block 1, Research BuildingNeptunus Technical CenterSHENZHEN 518000ChinaCHN
  • Phone+86 75 526411869
  • Fax+86 75 586391610
  • Websitehttps://www.interlong.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.